US Stock MarketDetailed Quotes
NKTR Nektar Therapeutics
- 1.3200
- -0.0600-4.35%
Close Apr 25 16:00 ET
- 1.3200
- 0.00000.00%
Pre 08:57 ET
242.38MMarket Cap-910P/E (TTM)
1.3700High1.2900Low1.05MVolume1.3600Open1.3800Pre Close1.41MTurnover0.65%Turnover RatioLossP/E (Static)183.62MShares1.750052wk High1.85P/B215.30MFloat Cap0.412652wk Low--Dividend TTM163.11MShs Float111.3600Historical High--Div YieldTTM5.80%Amplitude0.4126Historical Low1.3370Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Nektar Therapeutics Stock Forum
Update
A Bio research company with these financials but trading this low! How sad
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
1.14 and we moon
Update
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...
going up
News!
Benzinga· 1 min ago
– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period –
– New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQ...
No comment yet